首页> 外文期刊>Journal of experimental & clinical cancer research : >Zebrafish modeling reveals that SPINT1 regulates the aggressiveness of skin cutaneous melanoma and its crosstalk with tumor immune microenvironment
【24h】

Zebrafish modeling reveals that SPINT1 regulates the aggressiveness of skin cutaneous melanoma and its crosstalk with tumor immune microenvironment

机译:斑马鱼造型揭示了Spint1调节皮肤皮肤黑色素瘤及其串扰与肿瘤免疫微环境的侵略性

获取原文
           

摘要

Skin cutaneous melanoma (SKCM) is the most lethal form of skin cancer and while incidence rates are declining for most cancers, they have been steadily rising for SKCM. Serine protease inhibitor, kunitz-type, 1 (SPINT1) is a type II transmembrane serine protease inhibitor that has been shown to be involved in the development of several types of cancer, such as squamous cell carcinoma and colorectal cancer. We used the unique advantages of the zebrafish to model the impact of Spint1a deficiency in early transformation, progression and metastatic invasion of SKCM together with in silico analysis of the occurrence and relevance of SPINT1 genetic alterations of the SKCM TCGA cohort. We report here a high prevalence of SPINT1 genetic alterations in SKCM patients and their association with altered tumor immune microenvironment and poor patient survival. The zebrafish model reveals that Spint1a deficiency facilitates oncogenic transformation, regulates the tumor immune microenvironment crosstalk, accelerates the onset of SKCM and promotes metastatic invasion. Notably, Spint1a deficiency is required at both cell autonomous and non-autonomous levels to enhance invasiveness of SKCM. These results reveal a novel therapeutic target for SKCM.
机译:皮肤皮肤黑色素瘤(SKCM)是最致命的皮肤癌形式,而且发病率为大多数癌症的发病率也在下降,但它们对SKCM稳步上升。丝氨酸蛋白酶抑制剂,Kunitz型,1(Spint1)是II型跨膜丝氨酸蛋白酶抑制剂,已被证明参与若干类型的癌症,例如鳞状细胞癌和结肠直肠癌。我们利用Zebrafish的独特优势来模拟Spint1a缺乏在早期转化,进展和转移侵犯SKCM的影响,以及SkcM TCGA队列的Spint1遗传改变的发生和相关性的硅分析。我们在此报告了SKCM患者的SPINT1遗传改变的高度普及及其与肿瘤免疫微环境和患者存活率的改变的关联。斑马鱼模型表明,施用缺陷促进了致癌转化,调节肿瘤免疫微环境串扰,加速SKCM发作并促进转移性侵袭。值得注意的是,在细胞自主和非自治水平中需要施用荧光度,以提高SKCM的侵袭性。这些结果揭示了SKCM的新疗法靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号